NeuroPace Beats on EPS, Cuts 2026 Guidance to $91M–$92M

NeuroPace reported a loss of $0.03 per share on Thursday, beating the consensus estimate of an $0.11 loss by $0.08 — yet the same report carried a revenue miss and a cut to 2026 guidance. The two facts sit in tension, and both belong in any honest reading of the quarter.

Revenue reached $23.10 million against analyst expectations of $27.12 million. The company posted a negative net margin of 19.34% and a negative return on equity of 105.64%. On the conference call, management said RNS revenue grew just 1.4% year over year to $22.9 million, while total revenue fell 1.1% to $23.1 million.

What went wrong in the quarter?

Management attributed the shortfall to three causes:

• Operational disruptions at large accounts
• Sales-team transitions
• The lagged impact of exiting the SEEG distribution business

The company said it is seeing signs of recovery. It also said improvement will take several quarters. That second sentence deserves as much weight as the first.

How deep is the guidance cut?

NeuroPace lowered its 2026 revenue guidance to $91 million–$92 million, down from $99.5 million–$101.5 million previously. The new range implies full-year RNS growth of 10%–11%. The company expects an adjusted EBITDA loss of $8.5 million–$9.5 million for the year. It raised its gross-margin outlook and reduced expected operating expenses — cost discipline, in plain words, partially offsetting a weaker top line.

For 2027, management guided to RNS revenue growth of about 15%, with 10%–15% in the first half and 15%–20% in the second half. The outlook excludes any contribution from an IGE indication expansion and from service revenue. It also depends on improved commercial execution — the very thing that failed this quarter.

What catalysts did management promise?

The company laid out three regulatory timelines:

• An IGE amendment submission around year-end, with possible FDA approval by mid-2027
• Remote Care, submitted ahead of schedule, with approval possible in the second quarter of 2027
• An adolescent focal epilepsy study, with enrollment expected to finish in early 2027 and potential approval in late 2027 or early 2028

The company itself noted that all timelines remain subject to FDA review and study results. Promises dated 2027 and 2028 do not repair a 2026 guidance cut.

How did the stock and analysts respond?

NPCE fell $0.50 on Thursday to close at $12.02, near its 52-week low of $11.90 and well below its 52-week high of $19.60. Volume reached 146,170 shares against an average of 182,811. The fifty-day moving average sits at $13.41 and the two-hundred-day average at $14.81.

The balance sheet shows a current ratio of 4.94, a quick ratio of 3.91 and a debt-to-equity ratio of 4.97. Market capitalization stands at $412.57 million, with a P/E ratio of -21.09 and a beta of 1.98.

Analyst opinion splits. Guggenheim reissued a neutral rating on July 29; Weiss Ratings lowered the stock from sell (d-) to sell (e+) on October 2; Raymond James Financial set a $21.00 price objective on September 15; HC Wainwright reiterated a buy with a $20.00 objective on July 29; Cantor Fitzgerald reissued an overweight rating on September 15. MarketBeat counts one Strong Buy, six Buy, one Hold and one Sell rating — a consensus of Moderate Buy with an average target of $20.50, roughly 70% above the current price. Targets that far from the market price signal disagreement, not conviction.

The plain reading

An EPS beat built on cost control, a revenue miss built on execution failures, and a 2026 outlook cut of roughly $9 million at the midpoint: the catalysts are real but distant, and the recovery is promised, not delivered.